IMCC vs. FLGC, ABP, EDSA, PRPH, MEIP, UPXI, UBX, IBIO, MBRX, and ME
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Flora Growth (FLGC), Abpro (ABP), Edesa Biotech (EDSA), ProPhase Labs (PRPH), MEI Pharma (MEIP), Upexi (UPXI), Unity Biotechnology (UBX), iBio (IBIO), Moleculin Biotech (MBRX), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry.
IM Cannabis vs.
IM Cannabis (NASDAQ:IMCC) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.
In the previous week, Flora Growth had 4 more articles in the media than IM Cannabis. MarketBeat recorded 4 mentions for Flora Growth and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.47 beat Flora Growth's score of -0.59 indicating that IM Cannabis is being referred to more favorably in the media.
IM Cannabis has a net margin of -25.55% compared to Flora Growth's net margin of -30.99%. IM Cannabis' return on equity of -129.86% beat Flora Growth's return on equity.
Flora Growth has a consensus price target of $4.00, indicating a potential upside of 497.01%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than IM Cannabis.
7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 5.9% of IM Cannabis shares are held by insiders. Comparatively, 12.6% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Flora Growth received 9 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 60.00% of users gave Flora Growth an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.
IM Cannabis has higher revenue and earnings than Flora Growth. IM Cannabis is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
IM Cannabis has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
Summary
Flora Growth beats IM Cannabis on 10 of the 18 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis Competitors List
Related Companies and Tools
This page (NASDAQ:IMCC) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy IMCC Stock Free IMCC Stock Alerts